AstraZeneca reports positive outcomes from trial of Imfinzi

AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab) with standard-of-care fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in individuals with resectable, early-stage, and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.